All News

Nipple- and skin-sparing mastectomy is now an option for women, but it comes with choices and may not be for everyone.

For patients with stage 3 colorectal cancer and normal KRAS gene activity, Erbitux (cetuximab) did not extend survival when added to chemotherapy.

In two separate early-stage breast cancer studies, researchers examined the benefit of testing for traveling cancer cells that may have broken off the tumor site and additional surgery if those roaming cells were found.

Three drugs, which use different mechanisms to target cancer, highlighted at annual oncology meeting.

Finalist essay written by Greg Frazee nominating nurse Annette Graham, NP, AOCNP, from the Virginia Cancer Institute, for CURE's 2010 Extraordinary Healer Award contest.

Separate studies show that maintenance therapy, treatment given after initial therapy to prolong remission, can benefit patients with certain blood cancers.

A new chemotherapy drug, called eribulin, extended survival by two and a half months in patients with locally recurrent or metastatic breast cancer whose cancers continued to progress despite treatment with numerous other drugs.

Studies show how hypnosis can help patients deal with pain, fatigue, and anxiety.

Finalist essay written by Catherine Gilmore nominating nurse Jackie Broadway-Duren, MSN, FNP-BC, from M.D. Anderson Cancer Center, for CURE's 2010 Extraordinary Healer Award contest.

Continued use of the targeted drug Avastin (bevacizumab), after initial treatment with the drug and chemotherapy, helped slow progression of advanced ovarian cancer, according to a phase 3 study.

An investigational drug, Crizotinib (PF-02341066), which targets a newly discovered gene mutation in lung tumors, showed dramatic results in a small phase 1 clinical trial of metastatic non-small cell lung cancer patients.

Interim results from a phase 3 trial showed that radiation added to androgen-deprivation therapy (ADT) increased overall survival and decreased the risk of death from prostate cancer.

For metastatic melanoma patients who were out of treatment options, the immune system-targeted drug ipilimumab extended their lives by nearly four months compared with an investigational vaccine called gp100.

A large randomized study contradicted that notion in advanced non-small cell lung cancer when data showed that the standard combination chemotherapy, usually given to younger patients, was effective and safe in elderly patients.